These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 20524319)
1. Bortezomib for acute humoral rejection in two repeat transplant recipients. Hardinger KL; Alford K; Murillo D Clin Transpl; 2009; ():479-83. PubMed ID: 20524319 [TBL] [Abstract][Full Text] [Related]
2. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
3. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience. Hardinger KL; Alford K; Murillo D Clin Transpl; 2010; ():429-36. PubMed ID: 21696060 [TBL] [Abstract][Full Text] [Related]
10. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition for antibody-mediated rejection. Everly JJ; Walsh RC; Alloway RR; Woodle ES Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989 [TBL] [Abstract][Full Text] [Related]
13. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS Clin Transpl; 2009; ():407-14. PubMed ID: 20524306 [No Abstract] [Full Text] [Related]
14. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Cooper JE; Wiseman AC; Chan L Clin Transpl; 2009; ():455-9. PubMed ID: 20524314 [No Abstract] [Full Text] [Related]
15. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature. Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008 [TBL] [Abstract][Full Text] [Related]
16. Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature. Gheith O; Al-Otaibi T; Nampoory N; Halim M; Nair P; Saied T; Al-Waheeb S; Muzeirei I; Ibraheim M Exp Clin Transplant; 2012 Aug; 10(4):406-9. PubMed ID: 22746156 [TBL] [Abstract][Full Text] [Related]
17. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line? Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM Clin Transpl; 2009; ():425-9. PubMed ID: 20524309 [No Abstract] [Full Text] [Related]